Madan Jagasia, MBBS, MS, of the Vanderbilt University Medical Center discussed the next steps in treating acute graft versus host disease with ruxolitinib.
In a paper published in The BMJ, the authors provide a summary for the diagnosis, treatment, and monitoring of thyroid nodules.
A study published in Cancer suggests meeting the ACS guidelines for physical activity correlates with improved health-related quality of life and lower depression levels.
Mark Schroeder, MD, detailed 3 different potential treatments for acute graft versus host disease.
Kura Oncology’s leading drug candidate, tipifarnib, was granted fast track designation by the FDA to treat adults of T-cell lymphomas.
The new guidelines provide additional guidance for healthcare providers to better recognize and diagnose breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
The FDA approved isatuximab-irfc, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor.
An interim analysis of the ongoing phase Ib study of resiniferatoxin, administered via epidural route in patients with intractable cancer pain, has produced positive data.
The FDA granted priority review to a biologics license application for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
This study found racial and ethnic disparities in childhood and adolescent cancer survival for non-Hispanic black, non-Hispanic American Indian/Alaskan Native, non-Hispanic Asian or Pacific Islander, and Hispanic patients.